What is the first-line treatment for iron-deficiency anemia in a woman with heavy menstrual bleeding, including the recommended agent, dose, duration, supporting guideline, and which additional laboratory tests should be obtained to confirm the etiology?

First-Line Treatment for Iron-Deficiency Anemia in Women with Heavy Menstrual Bleeding

Start with oral ferrous sulfate 200 mg once daily (or twice daily if tolerated) for at least 3 months after hemoglobin normalization to replenish iron stores 1, 2. This represents the most cost-effective and guideline-supported first-line approach for most premenopausal women with IDA and heavy menstrual bleeding.

Treatment Agent, Dose, and Duration

Oral Iron (First-Line for Most Patients)

• Agent: Ferrous sulfate, ferrous fumarate, or ferrous gluconate
• Dose: 200 mg once daily (or 200 mg twice daily if tolerated) 1
• Alternative dosing: If not tolerated, reduce to one tablet every other day 2
• Duration: Continue for 3 months after hemoglobin normalizes to replenish iron stores 1, 2
• Expected response: Hemoglobin should rise by 1-2 g/dL within 4 weeks 3, 4

The 2021 British Society of Gastroenterology guidelines specifically recommend starting with one tablet per day rather than the older three-times-daily regimen, as lower doses improve tolerability with similar efficacy 2.

When to Use Intravenous Iron Instead

Consider IV iron as first-line in these specific situations 1, 5:

• Hemoglobin <10 g/dL
• Previous intolerance to oral iron (after trying at least two different oral preparations)
• Need for rapid correction (e.g., before surgery)
• Ongoing heavy bleeding where oral iron cannot keep pace

IV iron options 1, 3:

• Ferric carboxymaltose: 500-1000 mg over 15 minutes (most convenient, single high-dose option)
• Iron sucrose: 200 mg over 10 minutes (requires multiple doses)
• Iron dextran: 20 mg/kg over 6 hours (requires test dose due to anaphylaxis risk)
• Ferric derisomaltose (iron isomaltoside): Up to 1500-2000 mg single dose 5

Guideline Support

The 2011 and 2021 British Society of Gastroenterology guidelines provide the strongest evidence base 1, 2. These guidelines emphasize that:

• All patients with IDA should receive iron supplementation regardless of underlying cause
• Oral iron remains first-line unless specific contraindications exist
• Treatment must continue for 3 months post-normalization to replenish stores
• Premenopausal women with IDA commonly have menstrual blood loss as the primary etiology

The 2015 European consensus on IBD and 2024 expert consensus on IV iron support IV iron for specific indications but confirm oral iron as the standard first approach in uncomplicated cases 5, 3.

Laboratory Tests to Confirm Etiology

Initial Diagnostic Labs (Already Done)

• Hemoglobin: <12 g/dL in non-pregnant women confirms anemia 6
• Ferritin: <30 μg/L confirms iron deficiency (some guidelines use <45 ng/mL) 6, 7
• Mean corpuscular volume (MCV): Typically low (<80 fL) in IDA 1
• Transferrin saturation (TSAT): <20% supports iron deficiency 3, 7

Additional Labs to Confirm Heavy Menstrual Bleeding as Etiology

Screen for celiac disease (present in up to 4% of premenopausal women with IDA) 1:

• Tissue transglutaminase antibody (tTG) with total IgA level 1, 6
• If positive, confirm with upper endoscopy and small bowel biopsy

Test for Helicobacter pylori if IDA persists or recurs 1:

• Non-invasive testing (stool antigen or urea breath test)
• H. pylori can impair iron absorption and increase iron loss

Thyroid function tests:

• TSH to exclude hypothyroidism, which can worsen menstrual bleeding

Coagulation screening (if family history or clinical suspicion):

• Von Willebrand factor antigen and activity
• Factor VIII level
• Consider hematology referral if bleeding disorder suspected

Labs NOT Recommended

• Fecal occult blood testing: Insensitive and non-specific, not useful in IDA workup 1, 4
• Routine liver or renal function: Only if history suggests systemic disease 1

Monitoring and Follow-Up

At 4 weeks 2:

• Repeat hemoglobin to confirm response (should increase by 1-2 g/dL)
• If inadequate response: check compliance, consider malabsorption, ongoing blood loss, or switch to IV iron

After hemoglobin normalization 1, 2:

• Continue oral iron for 3 additional months to replenish stores
• Recheck hemoglobin and ferritin at 3 months, then every 3 months for 1 year
• Target ferritin >50 ng/mL (>100 ng/mL in some guidelines) 3, 7

Red cell distribution width (RDW) can predict recurrence: an increase ≥0.8% predicts anemia recurrence approximately 3 months before hemoglobin drops, with 82% sensitivity 8.

Common Pitfalls to Avoid

1. Stopping iron too early: Most failures occur because treatment stops when hemoglobin normalizes rather than continuing for 3 months to replenish stores 1, 2

2. Not addressing the underlying cause: While treating with iron, simultaneously manage heavy menstrual bleeding with hormonal contraceptives or other gynecologic interventions 9

3. Assuming dietary deficiency alone: Even with positive dietary history, complete GI evaluation may be needed if patient is >45 years or has concerning symptoms 1

4. Over-investigating young women: For asymptomatic premenopausal women <50 years with clear HMB, extensive GI investigation (colonoscopy) is not routinely needed unless there are GI symptoms or family history of colorectal cancer 1, 6

5. Not screening for celiac disease: This is missed in up to 4% of cases and is a simple blood test 1